The “composition of matter” patent is typically the first patent filed protecting a new chemical entity. However, drug development often results in different solid forms by way of polymorphs, salts, or cocrystals for example, than the initial med-chem creation. This talk will explore how solid form patents may protect these advancements either during the development process or afterwards when older APIs are being repositioned.
The Attendees will learn how key basic patent concepts apply to pharmaceutical products.
The Attendees will learn the application of pharmaceutical patent concepts and strategies to pharmaceutical solid forms.
The Applicants will be given public examples on how various pharmaceutical companies are deploying solid form patents.